Arcutis Biotherapeutics (ARQT) said Thursday that the US Food and Drug Administration approved the foam version of Zoryve for treating plaque psoriasis on the scalp and body in patients aged 12 and older.

Zoryve foam is a steroid-free, once-daily topical treatment that is now available across the US, the company said.

Arcutis said clinical trials showed Zoryve foam significantly improved symptoms such as itching and plaque clearance on both the scalp and body, with a favorable safety and tolerability profile.

The approved formulation is Zoryve topical foam 0.3%, which offers a convenient option for treating psoriasis in hard-to-reach, hair-bearing areas.

Shares of Arcutis Biotherapeutics were up nearly 1% in recent trading.

Price: 13.89, Change: +0.13, Percent Change: +0.94